What question did this study set out to answer?

This research aims to evaluate the safety, tolerability, and pharmacodynamics of canagliflozin in healthy men.

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows canagliflozin reduces renal glucose threshold in healthy subjects, indicating potential for diabetes management.

This research aims to evaluate the safety, tolerability, and pharmacodynamics of canagliflozin in healthy men.
Ascending single oral-dose phase 1 trial with 63 healthy men randomized to canagliflozin or placebo.
Canagliflozin was administered in various dosages (10-800 mg) to eight cohorts.
Calculated 24-h mean renal threshold for glucose and urinary glucose excretion were measured.
Canagliflozin decreased calculated 24-h mean renal threshold for glucose to approximately 60 mg/dl (p<0.05).
Mean 24-h urinary glucose excretion significantly increased with canagliflozin doses above 200 mg (exact rates not provided).
No hypoglycemia was reported, and adverse events were mostly mild.

Sha et al. (2011) studied this question.

View Full Paper

Ask AI

Bookmark